TELA Bio Inc. reports Q3 revenue of $20.7 million, up 9%

Reuters11-14

<a href="https://laohu8.com/S/TELA">TELA Bio</a> Inc. reports Q3 revenue of $20.7 million, up 9%

TELA Bio Inc. reported third quarter 2025 revenue of $20.7 million, representing a 9% increase compared to the same period in 2024. Gross profit for the quarter was $14.0 million, or 67.5% of revenue, up from $12.9 million, or 67.8% of revenue, in the third quarter of 2024. The revenue growth was primarily driven by new customer additions, increased international sales, and the U.S. launch of larger-sized OviTex PRS configuration, partially offset by a decrease in average selling prices for hernia products due to a higher share of smaller-sized units. The company revised its full year 2025 revenue guidance to at least 16% growth over 2024. As of September 30, 2025, cash and cash equivalents totaled $29.7 million. TELA Bio also closed a credit facility for up to $70.0 million with Perceptive Advisors, consisting of an initial $60.0 million loan and an additional $10.0 million available upon meeting certain conditions. The credit facility matures on November 14, 2030, and is interest-only until maturity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TELA Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9575463-en) on November 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583147511?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 05:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583147511","market":"fut","top_or_hot":-1,"title":"TELA Bio Inc. reports Q3 revenue of $20.7 million, up 9%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TELA\">TELA Bio</a> Inc. reports Q3 revenue of $20.7 million, up 9%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TELA Bio Inc. reported third quarter 2025 revenue of $20.7 million, representing a 9% increase compared to the same period in 2024. Gross profit for the quarter was $14.0 million, or 67.5% of revenue, up from $12.9 million, or 67.8% of revenue, in the third quarter of 2024. The revenue growth was primarily driven by new customer additions, increased international sales, and the U.S. launch of larger-sized OviTex PRS configuration, partially offset by a decrease in average selling prices for hernia products due to a higher share of smaller-sized units. The company revised its full year 2025 revenue guidance to at least 16% growth over 2024. As of September 30, 2025, cash and cash equivalents totaled $29.7 million. TELA Bio also closed a credit facility for up to $70.0 million with Perceptive Advisors, consisting of an initial $60.0 million loan and an additional $10.0 million available upon meeting certain conditions. The credit facility matures on November 14, 2030, and is interest-only until maturity.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TELA Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9575463-en) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TELA Bio Inc. reports Q3 revenue of $20.7 million, up 9%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTELA Bio Inc. reports Q3 revenue of $20.7 million, up 9%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-14 05:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TELA\">TELA Bio</a> Inc. reports Q3 revenue of $20.7 million, up 9%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TELA Bio Inc. reported third quarter 2025 revenue of $20.7 million, representing a 9% increase compared to the same period in 2024. Gross profit for the quarter was $14.0 million, or 67.5% of revenue, up from $12.9 million, or 67.8% of revenue, in the third quarter of 2024. The revenue growth was primarily driven by new customer additions, increased international sales, and the U.S. launch of larger-sized OviTex PRS configuration, partially offset by a decrease in average selling prices for hernia products due to a higher share of smaller-sized units. The company revised its full year 2025 revenue guidance to at least 16% growth over 2024. As of September 30, 2025, cash and cash equivalents totaled $29.7 million. TELA Bio also closed a credit facility for up to $70.0 million with Perceptive Advisors, consisting of an initial $60.0 million loan and an additional $10.0 million available upon meeting certain conditions. The credit facility matures on November 14, 2030, and is interest-only until maturity.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TELA Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9575463-en) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210150020.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL6YNG09:1","article_id":"2583147511","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583147511","pubTimestamp":1763067676,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TELA Bio Inc. reported third quarter 2025 revenue of $20.7 million, representing a 9% increase compared to the same period in 2024. Gross profit for the quarter was $14.0 million, or 67.5% of revenue, up from $12.9 million, or 67.8% of revenue, in the third quarter of 2024. The revenue growth was primarily driven by new customer additions, increased international sales, and the U.S. launch of larger-sized OviTex PRS configuration, partially offset by a decrease in average selling prices for hernia products due to a higher share of smaller-sized units. The company revised its full year 2025 revenue guidance to at least 16% growth over 2024. As of September 30, 2025, cash and cash equivalents totaled $29.7 million. TELA Bio also closed a credit facility for up to $70.0 million with Perceptive Advisors, consisting of an initial $60.0 million loan and an additional $10.0 million available upon meeting certain conditions. The credit facility matures on November 14, 2030, and is interest-onl","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","TELA":"TELA Bio, Inc.","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4198":"医疗保健用品","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","NDAQ":"纳斯达克OMX交易所","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC"},"translate_title":"TELA Bio Inc.报告第三季度收入为2070万美元，增长9%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TELA":0.9,"NDAQ":0.9},"content_text":"TELA Bio Inc. reports Q3 revenue of $20.7 million, up 9%\n    \n\n        TELA Bio Inc. reported third quarter 2025 revenue of $20.7 million, representing a 9% increase compared to the same period in 2024. Gross profit for the quarter was $14.0 million, or 67.5% of revenue, up from $12.9 million, or 67.8% of revenue, in the third quarter of 2024. The revenue growth was primarily driven by new customer additions, increased international sales, and the U.S. launch of larger-sized OviTex PRS configuration, partially offset by a decrease in average selling prices for hernia products due to a higher share of smaller-sized units. The company revised its full year 2025 revenue guidance to at least 16% growth over 2024. As of September 30, 2025, cash and cash equivalents totaled $29.7 million. TELA Bio also closed a credit facility for up to $70.0 million with Perceptive Advisors, consisting of an initial $60.0 million loan and an additional $10.0 million available upon meeting certain conditions. The credit facility matures on November 14, 2030, and is interest-only until maturity.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TELA Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9575463-en) on November 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583147511","isCrawlerRequest":true}